Last update 08 Aug 2025

Rigerna Therapeutics Co. Ltd

Private Company | Subsidiary Company|2022|Beijing Shi, China

Overview

Tags

Skin and Musculoskeletal Diseases
Other Diseases
Immune System Diseases
mRNA

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
mRNA1
Top 5 TargetCount
Uric acid1

Related

1
Drugs associated with Rigerna Therapeutics Co. Ltd
mUox@iLAND
Target
Uric acid
Mechanism
Uric acid inhibitors
Active Org.
Beijing Institute of TechnologyBeijing Institute of Technology [+1]
Originator Org.
Beijing Institute of TechnologyBeijing Institute of Technology [+1]
Active Indication
Hyperuricemia
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Rigerna Therapeutics Co. Ltd
CTR20253001
/ Not yet recruitingPhase 2
一项在原发性IgA肾病受试者中评价RG002C0106注射液的安全性、初步有效性及其药代/药效动力学特征的多中心、随机、双盲、安慰剂对照的IIa期临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety, preliminary efficacy, and pharmacokinetic/pharmacodynamic characteristics of RG002C0106 injection in subjects with primary IgA nephropathy
100 Clinical Results associated with Rigerna Therapeutics Co. Ltd
Login to view more data
0 Patents (Medical) associated with Rigerna Therapeutics Co. Ltd
Login to view more data
100 Deals associated with Rigerna Therapeutics Co. Ltd
Login to view more data
100 Translational Medicine associated with Rigerna Therapeutics Co. Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
mUox@iLAND
 ( Uric acid )		Hyperuricemia
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free